Crystal Structure of Thrombin in Complex with S-Variegin: Insights of a Novel Mechanism of Inhibition and Design of Tunable Thrombin Inhibitors

The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique ‘two-modes’ inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human α-thrombin:synthetic-variegin complex at 2.4 Å resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants.

[1]  Celeste B. Burness,et al.  Dabigatran Etexilate , 2012, Drugs.

[2]  E. Di Cera,et al.  Crystal Structure of Thrombin Bound to the Uncleaved Extracellular Fragment of PAR1* , 2010, The Journal of Biological Chemistry.

[3]  R. Kini,et al.  Noncompetitive Inhibitor of Thrombin , 2009, Chembiochem : a European journal of chemical biology.

[4]  R. Kini,et al.  Molecular diversity of anticoagulants from haematophagous animals , 2009, Thrombosis and Haemostasis.

[5]  R. Kini,et al.  Anticoagulants from hematophagous animals , 2008, Expert review of hematology.

[6]  J. Huntington.  How Na+ activates thrombin – a review of the functional and structural data , 2008, Biological chemistry.

[7]  A. Greinacher,et al.  The direct thrombin inhibitor hirudin , 2008, Thrombosis and Haemostasis.

[8]  J. Weitz,et al.  New Anticoagulants for Treatment of Venous Thromboembolism , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[9]  S. Macedo-Ribeiro,et al.  Isolation, Cloning and Structural Characterisation of Boophilin, a Multifunctional Kunitz-Type Proteinase Inhibitor from the Cattle Tick , 2008, PloS one.

[10]  F. S. Mathews,et al.  Structural identification of the pathway of long-range communication in an allosteric enzyme , 2008, Proceedings of the National Academy of Sciences.

[11]  P. Takáč,et al.  Variegin, a Novel Fast and Tight Binding Thrombin Inhibitor from the Tropical Bont Tick* , 2007, Journal of Biological Chemistry.

[12]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[13]  P. Schultz,et al.  Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin. , 2007, Journal of the American Chemical Society.

[14]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[15]  E. Di Cera,et al.  Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4 , 2007, Proceedings of the National Academy of Sciences.

[16]  J. Stassen,et al.  In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate , 2007, Thrombosis and Haemostasis.

[17]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[18]  R. Ajjan,et al.  Coagulation and atherothrombotic disease. , 2006, Atherosclerosis.

[19]  A. Weng,et al.  Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome. , 2005 .

[20]  E. Di Cera,et al.  Determinants of specificity in coagulation proteases , 2005, Journal of thrombosis and haemostasis : JTH.

[21]  J. Huntington,et al.  Molecular recognition mechanisms of thrombin , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  D. Champagne.  Antihemostatic strategies of blood-feeding arthropods. , 2004, Current drug targets. Cardiovascular & haematological disorders.

[23]  H. Nakatake,et al.  Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. , 2004, Journal of biochemistry.

[24]  J. Fareed,et al.  Small-molecule direct antithrombins: argatroban. , 2004, Best practice & research. Clinical haematology.

[25]  H. Nakatake,et al.  An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin. , 2001, Journal of biochemistry.

[26]  Y. Konishi,et al.  Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures. , 2000, Biochemistry.

[27]  E. Purisima,et al.  Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker. , 1997, Biochemistry.

[28]  E. Cera,et al.  Site-specific dissection of substrate recognition by thrombin , 1997, Nature Biotechnology.

[29]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[30]  J H Matthews,et al.  Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site. , 1996, Biophysical journal.

[31]  R. Huber,et al.  The ornithodorin‐thrombin crystal structure, a key to the TAP enigma? , 1996, The EMBO journal.

[32]  Y. Konishi,et al.  Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1', P2', and P3' substrate residues. , 1996, Biochemistry.

[33]  W. Bode,et al.  Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. , 1995, The EMBO journal.

[34]  C. Craik,et al.  Structural basis of substrate specificity in the serine proteases , 1995, Protein science : a publication of the Protein Society.

[35]  A. Tulinsky,et al.  Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. , 1994, Biochemistry.

[36]  R. Huber,et al.  The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. , 1994, The Journal of biological chemistry.

[37]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[38]  J. Maraganore,et al.  Thrombin-specific inhibition by and slow cleavage of hirulog-1. , 1992, The Biochemical journal.

[39]  H Oschkinat,et al.  The interaction of thrombin with fibrinogen. A structural basis for its specificity. , 1992, European journal of biochemistry.

[40]  D. Turk,et al.  The refined 1.9‐Å X‐ray crystal structure of d‐Phe‐Pro‐Arg chloromethylketone‐inhibited human α‐thrombin: Structure analysis, overall structure, electrostatic properties, detailed active‐site geometry, and structure‐function relationships , 1992, Protein science : a publication of the Protein Society.

[41]  A. Tulinsky,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991, Journal of molecular biology.

[42]  R. Huber,et al.  Refined structure of the hirudin-thrombin complex. , 1991, Journal of molecular biology.

[43]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[44]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[45]  R. Huber,et al.  The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989, The EMBO journal.

[46]  J. Hofsteenge,et al.  Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. , 1988, Biochemistry.

[47]  A. Baici,et al.  Interaction of site specific hirudin variants with α‐thrombin , 1988 .

[48]  J. Hofsteenge,et al.  Kinetics of the inhibition of thrombin by hirudin. , 1986, Biochemistry.

[49]  R. Yeh,et al.  Argatroban: update. , 2006, American heart journal.

[50]  P. Jagadeeswaran,et al.  Laser-induced thrombosis in zebrafish larvae: a novel genetic screening method for thrombosis. , 2006, Methods in molecular medicine.

[51]  P. Jagadeeswaran,et al.  Laser-Induced Thrombosis in Zebrafish Larvae , 2006 .

[52]  C. White,et al.  Thrombin-directed inhibitors: pharmacology and clinical use. , 2005, American heart journal.

[53]  J. Huntington,et al.  Directing thrombin. , 2005, Blood.

[54]  P. Afonine,et al.  research papers Acta Crystallographica Section D Biological , 2003 .

[55]  G N Murshudov,et al.  Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[56]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[57]  C. Tapparelli,et al.  Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. , 1995, Journal of enzyme inhibition.

[58]  A. Baici,et al.  Interaction of site specific hirudin variants with alpha-thrombin. , 1988, FEBS letters.

[59]  I. Kato,et al.  Protein inhibitors of proteinases. , 1980, Annual review of biochemistry.